The Malmo model for immune tolerance induction: impact of previous treatment on outcome
Carlborg, E ; Astermark, Jan LU ; Lethagen, Stefan LU ; Ljung, Rolf LU
and Berntorp, Erik
LU
(2000)
In Haemophilia
6(6).
p.639-639
- Abstract
- Ten patients, who had been treated according to the Malmo model for immune tolerance induction (ITI), were analysed regarding treatment with clotting factors and chemotherapy during the time period between inhibitor detection and ITI. Of the patients who were successfully rendered tolerant (n=6) all but one had received treatment with FVIII, either alone (n=1), or combined with cyclophosphamide (n=4). Of the patients who did not become tolerant, three of four had received treatment with FVIII during the inhibitor period but only one with FVIII and chemotherapy. The total amount of treatment received was in general much lower in the group that did not become tolerant. In individual cases, it appeared very clear that the inhibitor level and... (More)
- Ten patients, who had been treated according to the Malmo model for immune tolerance induction (ITI), were analysed regarding treatment with clotting factors and chemotherapy during the time period between inhibitor detection and ITI. Of the patients who were successfully rendered tolerant (n=6) all but one had received treatment with FVIII, either alone (n=1), or combined with cyclophosphamide (n=4). Of the patients who did not become tolerant, three of four had received treatment with FVIII during the inhibitor period but only one with FVIII and chemotherapy. The total amount of treatment received was in general much lower in the group that did not become tolerant. In individual cases, it appeared very clear that the inhibitor level and anamnestic response was substantially reduced prior to the ITI using the Malmo treatment model. We conclude that treatment of acute bleeds during the inhibitor period may be of importance for ITI and that the different response rates published for different immune tolerance regimens most likely do not reflect the true response rate for the respective regimen. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1117535
- author
- Carlborg, E
; Astermark, Jan
LU
; Lethagen, Stefan
LU
; Ljung, Rolf
LU
and Berntorp, Erik
LU
- organization
- publishing date
- 2000
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Haemophilia
- volume
- 6
- issue
- 6
- pages
- 639 - 639
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:11122389
- scopus:0033625967
- ISSN
- 1351-8216
- DOI
- 10.1046/j.1365-2516.2000.00436.x
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Coagulation Research Unit (013242510), Paediatric Hematologic Research Group (013243020), Emergency medicine/Medicine/Surgery (013240200)
- id
- 1400f4a7-9813-4c13-8a01-4c33a501b989 (old id 1117535)
- date added to LUP
- 2016-04-04 07:37:52
- date last changed
- 2025-01-05 21:43:05
@article{1400f4a7-9813-4c13-8a01-4c33a501b989,
abstract = {{Ten patients, who had been treated according to the Malmo model for immune tolerance induction (ITI), were analysed regarding treatment with clotting factors and chemotherapy during the time period between inhibitor detection and ITI. Of the patients who were successfully rendered tolerant (n=6) all but one had received treatment with FVIII, either alone (n=1), or combined with cyclophosphamide (n=4). Of the patients who did not become tolerant, three of four had received treatment with FVIII during the inhibitor period but only one with FVIII and chemotherapy. The total amount of treatment received was in general much lower in the group that did not become tolerant. In individual cases, it appeared very clear that the inhibitor level and anamnestic response was substantially reduced prior to the ITI using the Malmo treatment model. We conclude that treatment of acute bleeds during the inhibitor period may be of importance for ITI and that the different response rates published for different immune tolerance regimens most likely do not reflect the true response rate for the respective regimen.}},
author = {{Carlborg, E and Astermark, Jan and Lethagen, Stefan and Ljung, Rolf and Berntorp, Erik}},
issn = {{1351-8216}},
language = {{eng}},
number = {{6}},
pages = {{639--639}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Haemophilia}},
title = {{The Malmo model for immune tolerance induction: impact of previous treatment on outcome}},
url = {{http://dx.doi.org/10.1046/j.1365-2516.2000.00436.x}},
doi = {{10.1046/j.1365-2516.2000.00436.x}},
volume = {{6}},
year = {{2000}},
}